MarketCap
Facebook
X
Telegram
Genmab A/S Revenue | GMAB
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Genmab A/S
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 10.1 B | 5.37 B | 3.03 B | 2.37 B | 1.82 B | 1.13 B | 850 M | 664 M | 485 M | 351 M |
All numbers in DKK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.1 B | 351 M | 2.62 B |
Quarterly Revenue Genmab A/S
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 21.5 B | 5.4 B | 16.5 B | 4.2 B | - | - | - | - | - | - | 1.97 B | - | - | - | 5.45 B | - | - | - | 774 M | - | - | - | 510 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in DKK currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 21.5 B | 510 M | 7.04 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Geron Corporation
GERN
|
237 K | $ 1.21 | 0.83 % | $ 807 M |  USA |
 |
Gilead Sciences
GILD
|
29.4 B | $ 144.63 | 0.85 % | $ 180 B | USA |
 |
Gossamer Bio
GOSS
|
48.5 M | $ 10.65 | 0.37 % | $ 2.43 B | USA |
 |
GeoVax Labs
GOVX
|
2.49 M | $ 0.32 | 1.31 % | $ 307 K | USA |
 |
Grifols, S.A.
GRFS
|
7.21 B | $ 7.41 | 1.37 % | $ 5.04 B |  Spain |
 |
GlaxoSmithKline plc
GSK
|
32.7 B | $ 46.55 | 0.93 % | $ 189 B |  Britain |
 |
GT Biopharma
GTBP
|
27 K | $ 6.16 | 0.98 % | $ 34 M | USA |
 |
Halozyme Therapeutics
HALO
|
1.4 B | $ 108.31 | 2.73 % | $ 13 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
549 M | $ 14.31 | 0.77 % | $ 12.3 B |  China |
 |
Harmony Biosciences Holdings
HRMY
|
868 M | $ 39.92 | 0.71 % | $ 2.3 B | USA |
 |
Heron Therapeutics
HRTX
|
155 M | $ 0.37 | 6.44 % | $ 61.7 M | USA |
 |
iBio
IBIO
|
100 K | $ 1.12 | 0.89 % | $ 117 M | USA |
 |
ImmuCell Corporation
ICCC
|
27.6 M | $ 9.75 | 1.56 % | $ 88 M | USA |
 |
IDEAYA Biosciences
IDYA
|
219 M | $ 38.06 | 1.87 % | $ 3.37 B | USA |
 |
InflaRx N.V.
IFRX
|
29.3 K | $ 1.68 | 0.58 % | $ 113 M |  Germany |
 |
Immutep Limited
IMMP
|
10.3 M | $ 4.27 | 0.46 % | $ 6.22 B |  Australia |
 |
Immunome
IMNM
|
6.94 M | $ 21.17 | 1.29 % | $ 1.85 B | USA |
 |
Immuron Limited
IMRN
|
7.29 M | $ 1.07 | 0.46 % | $ 247 M | Australia |
 |
Innate Pharma S.A.
IPHA
|
9 M | $ 1.58 | 1.28 % | $ 142 M |  France |
 |
Incyte Corporation
INCY
|
5.14 B | $ 114.13 | 0.06 % | $ 22.3 B | USA |
 |
InMed Pharmaceuticals
INM
|
4.94 M | $ 1.33 | 0.01 % | $ 5.54 M |  Canada |
 |
INmune Bio
INMB
|
50 K | $ 1.94 | 0.52 % | $ 48 M | USA |
 |
Inovio Pharmaceuticals
INO
|
65.3 K | $ 1.15 | 2.05 % | $ 53.9 M | USA |
 |
Insmed Incorporated
INSM
|
606 M | $ 103.83 | 2.33 % | $ 20.7 B | USA |
 |
Innoviva
INVA
|
411 M | $ 20.64 | 0.68 % | $ 1.39 B | USA |
 |
Iovance Biotherapeutics
IOVA
|
264 M | $ 14.15 | 0.63 % | $ 5.06 M | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
47.7 M | $ 3.65 | 0.27 % | $ 591 M | USA |
 |
Inventiva S.A.
IVA
|
9.2 M | $ 3.48 | 2.89 % | $ 208 M | France |
 |
Jaguar Health
JAGX
|
11.5 M | $ 4.73 | 29.23 % | $ 11 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
4.27 B | $ 236.04 | 0.16 % | $ 14.4 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
94.2 B | $ 252.93 | 0.03 % | $ 609 B | USA |
 |
Kala Pharmaceuticals
KALA
|
3.89 M | $ 0.36 | 0.86 % | $ 2.93 M | USA |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
678 M | $ 76.31 | 0.69 % | $ 5.66 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
146 M | $ 0.67 | 1.51 % | $ 7.33 K | USA |
 |
Keros Therapeutics
KROS
|
244 M | $ 11.52 | 1.41 % | $ 429 M | USA |
 |
Krystal Biotech
KRYS
|
389 M | $ 334.85 | 3.9 % | $ 9.69 B | USA |
 |
Kura Oncology
KURA
|
67.5 M | $ 10.62 | 0.09 % | $ 931 M | USA |
 |
Kymera Therapeutics
KYMR
|
39.2 M | $ 109.85 | 2.29 % | $ 9.28 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
42 K | $ 9.35 | 0.86 % | $ 143 M | Australia |
 |
Lineage Cell Therapeutics
LCTX
|
14.6 M | $ 0.93 | 2.73 % | $ 214 M | USA |
 |
Legend Biotech Corporation
LEGN
|
627 M | $ 18.77 | 1.1 % | $ 6.92 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
268 M | $ 306.77 | 1.26 % | $ 5.93 B | USA |
 |
Longeveron
LGVN
|
1.2 M | $ 2.51 | 0.39 % | $ 44.1 B | USA |